Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
Provided By Globe Newswire
Last update: May 22, 2023
- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF -
- Results reinforce rencofilstat’s direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH’ paired biopsy trial -
Read more at globenewswire.com0.3916
0 (-0.61%)
Find more stocks in the Stock Screener
HEPA Latest News and Analysis
2 days ago - ChartmillGet insights into the top gainers and losers of Wednesday's after-hours session.Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
